Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study

Diabetes and Metabolism

Volumn 30, Issue 1, 2004, Pages 81-89

  Rizzo, M R ^a   Barbieri, M ^a   Grella, R ^a   Passariello, N ^a   Barone, M ^b   Paolisso, G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Glimepiride; Hyperglycaemic glucose clamp; Insulin secretion; Meal test; Postprandial glycemia; Repaglinide

Indexed keywords

GLIMEPIRIDE; GLUCOSE; INSULIN; REPAGLINIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FASTING BLOOD GLUCOSE; FASTING INSULIN BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERGLYCEMIC GLUCOSE CLAMP TECHNIQUE; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TEST MEAL;

EID: 1842454645     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70093-9     Document Type: Article

References (26)

1. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis, 1998, 137, S65-S73.
2. Ambavane V, Patil R, Ainapure SS. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. J Postgrad Med, 2002, 48, 3, 246-8.
3. Landgraf R, Bilo HJ, Muller PG. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol, 1999, 55, 165-71.
4. Owens DR, Luzio SD, Ismail I, Bayer T. Increased prandial insulin secretion following a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care, 2000, 23, 513-23.
5. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycemia in the treatment of type 2 diabetes?. Int J Obes Relat Metab Disord, 2000, 24, S21-S31.
6. Schernthaner G, Di Mario U, Grimaldi A. The European GUIDE study: head-to head comparison of efficacy and safety of two once daily sulfanylureas gliclazide MR and glimepiride in 845 Type 2 diabetic patients. Diabetologia, 2003, 46, A281.
7. Raptis SA, Dimitriadis GD. Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers. Exp Clin Endocrinol Diabetes, 2001, 109, S265-87.
8. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol, 1979, 237, E214-23.
9. Mitrakou A, Vuorinen-Markkola H, Raptis G, et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp. J Clin Endocrinol Metab, 1992, 75, 379-82.
10. Matsuda MD, De Fronzo RA. In vivo measurement of insulin sensitivity in humans. Clinical research in diabetes and obesity, 1997, 23-65.
11. Shapiro ET, Tillil H, Miller MA, et al. Insulin secretion and clearance. Comparison after oral and intravenous glucose. Diabetes, 1987, 36, 1365-71.
12. Katz AI, Lindheimer MD, Mako ME, Rubenstein AH. Peripheral metabolism of insulin, proinsulin, and C-peptide in the pregnant rat. J Clin Invest, 1975, 56,1608-14.
13. Shuster LT, Go VL, Rizza RA, O'Brien PC, Service FJ. Incretin effect due to increased secretion and decreased clearance of insulin in normal humans. Diabetes, 1988, 37, 200-3.
14. Madison LL. Role of insulin in the hepatic handling of glucose. Arch Intern Med, 1969, 123, 284-92.
15. Gregorio F, Ambrosi F, Cristallini S, Filipponi P, Sauteusanio F. Effects of glimepiride on insulin and glucagone release from isolated rat pancreas at different glucose concentrations. Acta Diabetol, 1996, 33, 25-9.
16. Ledercq-Meyer V, Akkan AG, Marchand J, Malaisse WJ. Effects of glimepiride and glibenclamide on insulin and glucagons secretion by the perfused rat pancreas. Biochem Pharmacol, 1991, 42, 1634-7.
17. Muller M, Satoh Y, Greisen K. Extrapancreatic effects of sulfonylureas: a comparison between glimepiride and conventional sulphonylureas. Diabetes Res Clin Pract, 1995, 28, S115-37.
18. Korytkowski M, Thomas A, Reid L, Tedesco MB, Goodning WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care, 2002, 25, 1607-11.
19. Smith NL, Barzilay JI, Shaffer D, et al. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly. The cardiovascular health study. Arch Intern Med, 2002, 162, 209-16.
20. Meigs JB, Nathan DM, D'Agostino RB, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham offspring study. Diabetes Care, 2002, 25, 1845-50.
21. Moses R, Gomis R, Brown Fransen K, Clauson P. The efficacy and safety of repaglinide used as a flexible prandial glucose regulator in patients with Type 2 diabetes: a multicentre, randomised, placebo-controlled, double-blind study. Diabetic Med, 1999, 16, 95.
22. Paolisso G, Tagliamonte MR, Rizzo MR, et al. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia, 1998, 41, 1127-32.
23. Paolisso G, Howard BV. Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus. Diabet Med, 1998, 15, 360-6.
24. Manzella D, Barbieri M, Rizzo MR, et al. Role of free acids on cardiac autonomic nervous systemic in noninsulin-dependent diabetic patients: effects of metabolic control. J Clin Endocrinol Metab, 2001, 86, 2768-74.
25. Paolisso G, Schenn A, Albert A, Lefebvre PJ. Effects of pulsatile delivery of insulin and glucagon in man. Am J Physiol (Endocrinol Metab), 1989, 275, E686-96.
26. Paolisso G, Sgambato S, Gentile S, et al. Advantageous metabolic effects of pulsatile insulin delivery in non-insulin dependent diabetic subjects. J Clin Endocrinol Metab, 1988, 67, 1005-10.